未登录

M

Michael Zhuo Wang

university of kansas

H指数:22

被引数:4,570

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative transcriptomic profiling of drug-metabolizing enzymes and drug transporters in rabbit ocular subtissues, liver, and duodenum

兔眼亚组织、肝脏和十二指肠中药物代谢酶和药物转运体的比较转录组分析

Drug Metabolism and Disposition

IF4

2025-05-200

OA

N-substituted-4-(pyridin-4-ylalkyl)piperazine-1-carboxamides and related compounds as Leishmania CYP51 and CYP5122A1 inhibitors

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2024-11-012

PRE

CYP5122A1 encodes an essential sterol C4-methyl oxidase in Leishmania donovani and determines the antileishmanial activity of antifungal azoles

NATURE COMMUNICATIONS

IF15.7

2024-10-311

OAAI

Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2024-07-091

PRE

Sterol profiling of Leishmania parasites using a new HPLC-tandem mass spectrometry-based method and antifungal azoles as chemical probes reveals a key intermediate sterol that supports a branched ergosterol biosynthetic pathway

INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE

IF3.4

2022-12-0114

OAAI

Cellular Target Deconvolution of Small Molecules Using a Selection-Based Genetic Screening Platform

ACS CENTRAL SCIENCE

IF10.4

2022-09-224

OAAI

Development of a UPLC-MRM-based targeted proteomic method to profile subcellular organelle marker proteins from human liver tissues

SCIENTIFIC REPORTS

IF3.9

2022-06-292

OAAI

Synthesis and Antileishmanial Evaluation of Arylimidamide-Azole Hybrids Containing a Phenoxyalkyl Linker

ACS INFECTIOUS DISEASES

IF3.8

2021-02-046

OA

Minimal Cerebrospinal Fluid Concentration of Miltefosine despite Therapeutic Plasma Levels during the Treatment of Amebic Encephalitis

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2019-12-208

OAAI

Improving Eflornithine Oral Bioavailability and Brain Uptake by Modulating Intercellular Junctions With an E-cadherin Peptide

JOURNAL OF PHARMACEUTICAL SCIENCES

IF3.8

2019-12-016

PREAI

Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis

细胞外囊泡的概述，其来源，组成，目的以及用于外泌体隔离和分析的方法

IF5.2

2019-07-152.2K

OAAI

Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-01-0113

OAAI

Cytochrome P450 and flavin-containing monooxygenase families: age-dependent differences in expression and functional activity

PEDIATRIC RESEARCH

IF3.1

2017-11-0145

OAAI

The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in goat and dog models

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2017-06-2822

OAAI

Synthesis of novel amide and urea derivatives of thiazol-2-ethylamines and their activity against Trypanosoma brucei rhodesiense

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2016-06-0130

OAAI

Antileishmanial Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines (vol 57, pg 5141, 2014)

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2016-01-120

PREAI

SAR refinement of antileishmanial N2,N4-disubstituted quinazoline-2,4-diamines

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2015-08-0132

OAAI

In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2014-08-0118

OAAI

Pharmacokinetic Comparison To Determine the Mechanisms Underlying the Differential Efficacies of Cationic Diamidines against First- and Second-Stage Human African Trypanosomiasis

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2014-07-0121

OAAI

Antileishmanial Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2014-06-1776

OAAI